Wednesday, May 20, 2026

Datametrex Secures Rights To Sell And Distribute Rapid COVID-19 Antigen Test Kits

Datametrex AI (TSXV: DM) this morning announced that it has secured the rights to sell and distribute a rapid antigen detection kit from South Korean manufacturer PCL Inc. The main benefit of the test is that with 97% accuracy, they produce results in as little as 5 to 10 minutes with no extra equipment being required for the consumer.

Datametrex AI's Logo

The test hosts advantages over others on the market solely as a result of the rapid testing nature of the product, combined with the lack of additional equipment being needed to conduct the test. The test is a method of measuring the presence of a COVID-19 infection via an in-vitro diagnostic medical device. It detects antigen of the SARS-CoV-2 virus from a persons oropharyngeal and nasopharyngeal secretions. Like a simple pregnancy test, if antigens are found a colored line appears in the T line area.

It’s said that the test has a clinical sensitivity, i.e., the ability to confirm the actual positive of the approved person, of 100%, and the clinical specificity, i.e the ability to confirm the actual negative of the negative person, of 97.78%. The antigen test has been awarded numerous certifications, including CE, Korea FDA, UNGM and more. It’s also been approved by the EU, Qatar, United Arab Emirates, India, Russia, Ecuador, Guatemala and Colombia.

“According to the manufacturer, PCL, this test can detect antigens of COVID-19 from a swab in the nose or throat and provide results in 10 minutes with over 97% accuracy. These almost-instant kits can be easily used at home. With the rise of cases in the United States and throughout the world, we at Datametrex believes it is critical to test and protect.”

Marshall Gunter, CEO of Datametrex

The strong benefit of the instant antigen kits that require no additional equipment, is that they can be conducted at home easily, with nearly instant results. This eliminates excessive wait times as high as 3-5 days or more previously experienced by individuals that have had other forms of COVID-19 tests performed.

Datametrex AI last traded at $0.15 on the TSX Venture.


FULL DISCLOSURE: DataMetrex AI Limited is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DataMetrex AI Limited on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

First Majestic Q1 Earnings: A Bang Up Quarter

Copper’s Structural Shortage May Be Here to Stay | Colin Joudrie – Selkirk Copper

Why Barrick’s “Strong” Quarter Wasn’t So Strong | Q1 2026 Earnings

Recommended

Altamira Gold Extends Maria Bonita Footprint with 110 Metre Step-Out

Son of Mango Founder Arrested Over Billionaire Father’s Fatal Cliff Fall

Related News

Datametrex AI Sees Medi-Call Launch In-Person Care Beta

Following the launch of its Medi-Call mobile app just days ago, Datametrex AI (TSXV: DM)...

Monday, November 1, 2021, 08:12:45 AM

Datametrex To Sell Health Canada Approved COVID-19 Test Kits

Datametrex AI (TSXV: DM) announced this morning that it has obtained non-exclusive rights to a...

Monday, May 11, 2020, 10:56:16 AM

Internet Of Things Books First Purchase Order For ThermalPass, Over 100 Inquiries Received On Product

Internet of Things Inc (TSXV: ITT) this morning released to the market that it has...

Tuesday, June 23, 2020, 09:14:52 AM

US Posts Another 4M Jobless Claims; Over 26M in Last 5 Weeks

This morning the Department of Labor announced the initial jobless claimes for the week ended...

Thursday, April 23, 2020, 10:23:46 AM

WHO Warns Coronavirus Outbreaks Have Not Reached Peak in Americas Yet

As the number of coronavirus cases reaches 10 million worldwide, the World Health Organization (WHO)...

Thursday, June 25, 2020, 08:04:00 PM